C520 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Diversified Musculoskeletal Care PortfolioA portfolio spanning reconstruction, trauma, prevention and rehabilitation gives Enovis multiple demand channels within musculoskeletal care. This breadth can support cross-selling, reduce reliance on one procedure category, and deepen relationships with hospitals, surgeons and other care providers over the medium term.
Positive And Improving Cash GenerationPositive and improving operating cash flow indicates that the business is generating internal liquidity despite reported losses. TTM free cash flow also provides funding for investment and debt service, although sustained conversion still needs to be demonstrated through a full operating cycle.
Expansion Into Surgical RoboticsAdding robotic automation and enabling technologies broadens Enovis beyond conventional implants and instruments, potentially strengthening its surgical platform and strategic relevance to hospitals. The Grenoble center of excellence may also build specialized capabilities that support future product development and adoption.
Bears Say
Severe And Persistent Reported LossesVery large net losses and deeply negative margins show that Enovis has not yet demonstrated durable earnings power. Continued losses can limit reinvestment flexibility, weaken returns on the existing asset base, and make future operating performance highly dependent on a successful profitability recovery.
Higher Leverage And Financing ExposureThe sharp increase in leverage leaves debt near the level of equity and reduces financial flexibility while profitability remains weak. Higher obligations can constrain capital allocation, increase sensitivity to operating setbacks, and make it harder to fund strategic initiatives without relying on additional borrowing.
Robotics Deal Creates Near-term Margin And Funding PressureAlthough the robotics acquisition expands the platform, its funding will draw on cash and the revolving credit facility while management expects a near-term EBITDA margin headwind. These effects could pressure cash conversion and leverage before anticipated margin improvement from 2028 onward.
Enovis News
C520 FAQ
What was Enovis’s price range in the past 12 months?
Currently, no data Available
What is Enovis’s market cap?
Enovis’s market cap is CHF890.42M.
When is Enovis’s upcoming earnings report date?
Enovis’s upcoming earnings report date is Nov 11, 2026 which is in 41 days.
How were Enovis’s earnings last quarter?
Enovis released its earnings results on Aug 06, 2026. The company reported CHF0.753 earnings per share for the quarter, beating the consensus estimate of CHF0.708 by CHF0.044.
Is Enovis overvalued?
According to Wall Street analysts Enovis’s price is currently Undervalued.
Does Enovis pay dividends?
Enovis does not currently pay dividends.
What is Enovis’s EPS estimate?
Enovis’s EPS estimate is 0.65.
How many shares outstanding does Enovis have?
Enovis has 57,669,495 shares outstanding.
What happened to Enovis’s price movement after its last earnings report?
Enovis reported an EPS of CHF0.753 in its last earnings report, beating expectations of CHF0.708. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Enovis?
Currently, no hedge funds are holding shares in CH:C520
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enovis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF32.15 (― Upside)
CHF32.15 (― Upside)
Blogger Sentiment
Bullish
CH:C520 Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth CHF372.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.78%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-25.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Enovis
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
C520 Company Deck
C520 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed solid operational execution and clear commercial momentum—particularly in Recon and extremities—with meaningful innovation catalysts (Arvis, Nebula), margin expansion at the gross level, EPS growth, and improved free cash flow. However, offsetting risks include tariff costs (~$4M), international volatility including Middle East exposure (~$1–2M/month), a Q1 selling-days headwind (~240 bps), a conservative stance on guidance, and an SEC-driven change to adjusted EBITDA presentation that reduces non-GAAP comparability. On balance, positive fundamental performance and a constructive outlook outweigh the near-term headwinds and reporting adjustments.View all CH:C520 earnings summariesC520 Stock 12 Month Forecast
Average Price Target
―Conmed
―
Integra Lifesciences
―
Smith & Nephew Snats
―
Stryker
―
Zimmer Biomet Holdings
―